<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to the humoral response, a 3-year follow-up study of 176 SARS patients showed that the level of IgM peaked at ~1 month after symptoms onset, and IgG peaked at 2â€“4 months (
 <xref rid="B90" ref-type="bibr">90</xref>). Patients with a longer illness period showed a lower neutralizing antibody response compared to patients with a shorter illness duration (
 <xref rid="B91" ref-type="bibr">91</xref>). It was reported that vaccine-elicited, neutralizing monoclonal antibody (MAb) targeting the S protein of SARS-CoV facilitates viral entry into host cells and enhances viral infectivity (
 <xref rid="B92" ref-type="bibr">92</xref>). This phenomenon is the so called antibody-dependent enhancement (ADE) (
 <xref rid="B69" ref-type="bibr">69</xref>), which is regarded as a great burden for vaccine development.
</p>
